Childhood Hematological Malignancies Training Program

项目总结/摘要 血液系统恶性肿瘤是最常见的儿童肿瘤，尽管在生存方面取得了显着进展， 率，仍然是癌症死亡的主要原因。在过去的十年里， 这些肿瘤的遗传基础，但将这些发现转化为对肿瘤基础的机械见解， 然而，在肿瘤发生和治疗反应方面，以及在新的诊断和治疗方法中的应用仍然有限。 提高恶性血液病儿童的预后依赖于独立研究者的培训 具有基因组分析、实验建模、转化科学和临床前建模方面的专业知识， 儿童恶性血液病虽然一些T32培训计划提供儿童癌症培训， 没有一个专门致力于血液恶性肿瘤的培训或利用富人的培训计划。 儿科癌症基因组计划的基因组发现的基础。拟议的培训计划 将为下一代科学家提供多学科的技能和知识， 儿童恶性血液病研究领域的领导者。该计划将培养三名 前三年有博士后研究员，第四年和第五年有四名研究员，另有一个职位 由St Jude赞助。该计划将提供丰富的培训经验，由具有不同背景的教师提供支持。 专业知识，包括由科学和临床研究人员组成的每个受训者的导师团队; 内部执行委员会，审查计划进度并协助培训计划的制定， 协调培训活动;一个由五名国家儿童领导人组成的外部咨询委员会 癌症研究和博士后培训;提供基因组学培训的专门讲座/研讨会系列， 遗传学、病理学、生物统计学、实验建模、基因组编辑、免疫治疗、临床前研究 和临床试验设计;培训生日，包括培训生和特邀演讲者的演讲;科学 和赠款写作;要求学员提交外部赠款资助申请不迟于 研究金第二年;以及详细评价受训人员的进展情况。学员将密切 与St Jude Comprehensive Cancer的丰富的基础到转化研究活动组合相结合 中心血液肿瘤计划，协调基础科学发现的翻译， 临床试验该计划将提供一个无与伦比的机会，培训科学家，以解决关键的未满足的需求 儿童恶性血液病

PROJECT SUMMARY/ABSTRACT Hematological malignancies are the commonest childhood tumors, and despite remarkable advances in survival rates, remain a leading cause of cancer death. The last decade has witnessed great progress in understanding the genetic basis of these tumors, but translating these discoveries into mechanistic insight into the basis of tumorigenesis and treatment response, and into new diagnostic and therapeutic approaches remains limited. Advancing outcomes for children with hematologic malignancies is reliant on training independent investigators with expertise in genomic analysis, experimental modeling, translational science and preclinical modeling of childhood hematological malignancies. Although some T32 training program provide training in childhood cancer, none are solely devoted to training in hematological malignancies or a training program that utilizes the rich foundation of genomic discoveries from the Pediatric Cancer Genome Project. The proposed training program will equip the next generation of scientists with the skills and knowledge from multiple disciplines to become leaders in the field of childhood hematological malignancy research. The proposed program will train three postdoctoral fellows in the first three years, and four fellows in years four and five, with an additional position supported by St Jude. The program will provide an enriched training experience supported by faculty with diverse expertise, including mentorship teams for each trainee consisting of scientific and clinical investigators; a T32 Internal Executive Committee that reviews program progress and assists with training program development and coordination of training activities; an External Advisory Committee comprised of five national leaders in childhood cancer research and postdoctoral training; a dedicated lecture/seminar series providing training in genomics, genetics, pathology, biostatistics, experimental modeling, genome editing, immunotherapy, preclinical studies and clinical trial design; a trainee day featuring trainee and invited speaker presentations; training in scientific and grant writing; the requirement that trainees submit external grant funding applications no later than the second year of the fellowship; and detailed evaluation of the progress of trainees. Trainees will be closely integrated with the rich portfolio of basic to translational research activities of the St Jude Comprehensive Cancer Center Hematological Malignancies Program, which coordinates translation of basic science discoveries to clinical trials. This program will provide an unrivalled opportunity to train scientists to address critical unmet needs in childhood hematological malignancies.